JPH11502419A - Ｌｓｄのｎ−１−カルボキシアルキル誘導体 - Google Patents

Ｌｓｄのｎ−１−カルボキシアルキル誘導体

Info

Publication number: JPH11502419A
Authority: JP; Japan
Prior art keywords: lsd; complex; enzyme; antibody; protein
Prior art date: 1995-11-20
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

JP9519960A

Other languages

English (en)

Japanese (ja)

Inventor

エフ．シグラー，ジェラルド

Original Assignee

ベーリンガーマンハイムコーポレイション

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-11-20

Filing date

1996-11-20

Publication date

1999-03-02

1996-11-20 Application filed by ベーリンガーマンハイムコーポレイション filed Critical ベーリンガーマンハイムコーポレイション

1999-03-02 Publication of JPH11502419A publication Critical patent/JPH11502419A/ja

Status Ceased legal-status Critical Current

Links

102000004190 Enzymes Human genes 0.000 claims abstract description 92
108090000790 Enzymes Proteins 0.000 claims abstract description 92
238000000034 method Methods 0.000 claims abstract description 61
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 44
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 39
229920001184 polypeptide Polymers 0.000 claims abstract description 38
230000002163 immunogen Effects 0.000 claims abstract description 37
125000000217 alkyl group Chemical group 0.000 claims abstract description 25
125000004432 carbon atom Chemical group C* 0.000 claims abstract description 24
125000003118 aryl group Chemical group 0.000 claims abstract description 19
125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 19
239000000126 substance Substances 0.000 claims abstract description 18
229920001308 poly(aminoacid) Polymers 0.000 claims abstract description 6
239000003153 chemical reaction reagent Substances 0.000 claims description 56
238000006243 chemical reaction Methods 0.000 claims description 26
108090000623 proteins and genes Proteins 0.000 claims description 24
102000004169 proteins and genes Human genes 0.000 claims description 23
239000000758 substrate Substances 0.000 claims description 22
102000005936 beta-Galactosidase Human genes 0.000 claims description 19
108010005774 beta-Galactosidase Proteins 0.000 claims description 19
230000027455 binding Effects 0.000 claims description 13
210000002700 urine Anatomy 0.000 claims description 13
150000001875 compounds Chemical class 0.000 claims description 12
230000000694 effects Effects 0.000 claims description 8
239000002207 metabolite Substances 0.000 claims description 8
230000015572 biosynthetic process Effects 0.000 claims description 7
230000009137 competitive binding Effects 0.000 claims description 7
239000011541 reaction mixture Substances 0.000 claims description 4
238000003018 immunoassay Methods 0.000 claims description 3
230000005764 inhibitory process Effects 0.000 claims description 3
230000002401 inhibitory effect Effects 0.000 claims description 2
238000006911 enzymatic reaction Methods 0.000 claims 1
230000002485 urinary effect Effects 0.000 claims 1
239000000543 intermediate Substances 0.000 abstract description 3
239000000941 radioactive substance Substances 0.000 abstract description 3
PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 abstract description 2
230000002194 synthesizing effect Effects 0.000 abstract 1
229950002454 lysergide Drugs 0.000 description 135
VAYOSLLFUXYJDT-RDTXWAMCSA-N Lysergic acid diethylamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N(CC)CC)C2)=C3C2=CNC3=C1 VAYOSLLFUXYJDT-RDTXWAMCSA-N 0.000 description 113
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 53
238000003556 assay Methods 0.000 description 40
239000000243 solution Substances 0.000 description 25
239000012491 analyte Substances 0.000 description 21
239000003814 drug Substances 0.000 description 21
229940079593 drug Drugs 0.000 description 20
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
230000036039 immunity Effects 0.000 description 18
235000018102 proteins Nutrition 0.000 description 18
239000000523 sample Substances 0.000 description 18
238000002360 preparation method Methods 0.000 description 17
239000000370 acceptor Substances 0.000 description 16
239000000047 product Substances 0.000 description 15
AVBGNFCMKJOFIN-UHFFFAOYSA-N triethylammonium acetate Chemical compound CC(O)=O.CCN(CC)CC AVBGNFCMKJOFIN-UHFFFAOYSA-N 0.000 description 12
230000003053 immunization Effects 0.000 description 11
238000002649 immunization Methods 0.000 description 11
238000004128 high performance liquid chromatography Methods 0.000 description 10
108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 9
239000000203 mixture Substances 0.000 description 9
238000003127 radioimmunoassay Methods 0.000 description 9
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
239000008363 phosphate buffer Substances 0.000 description 7
125000003396 thiol group Chemical group [H]S* 0.000 description 7
241001465754 Metazoa Species 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
238000004458 analytical method Methods 0.000 description 6
230000008878 coupling Effects 0.000 description 6
238000010168 coupling process Methods 0.000 description 6
238000005859 coupling reaction Methods 0.000 description 6
-1 fluorescein compounds Chemical class 0.000 description 6
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 6
102000014914 Carrier Proteins Human genes 0.000 description 5
108010078791 Carrier Proteins Proteins 0.000 description 5
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 5
238000013459 approach Methods 0.000 description 5
239000012876 carrier material Substances 0.000 description 5
239000012634 fragment Substances 0.000 description 5
239000012312 sodium hydride Substances 0.000 description 5
229910000104 sodium hydride Inorganic materials 0.000 description 5
238000003756 stirring Methods 0.000 description 5
IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
235000001014 amino acid Nutrition 0.000 description 4
210000001124 body fluid Anatomy 0.000 description 4
238000006555 catalytic reaction Methods 0.000 description 4
238000001514 detection method Methods 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 4
230000004044 response Effects 0.000 description 4
239000007858 starting material Substances 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical class CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
102000002464 Galactosidases Human genes 0.000 description 3
108010093031 Galactosidases Proteins 0.000 description 3
ZAGRKAFMISFKIO-UHFFFAOYSA-N Isolysergic acid Natural products C1=CC(C2=CC(CN(C2C2)C)C(O)=O)=C3C2=CNC3=C1 ZAGRKAFMISFKIO-UHFFFAOYSA-N 0.000 description 3
239000007990 PIPES buffer Substances 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
150000001413 amino acids Chemical class 0.000 description 3
125000003277 amino group Chemical group 0.000 description 3
230000008033 biological extinction Effects 0.000 description 3
239000010839 body fluid Substances 0.000 description 3
235000011089 carbon dioxide Nutrition 0.000 description 3
125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 3
230000000295 complement effect Effects 0.000 description 3
230000021615 conjugation Effects 0.000 description 3
230000009260 cross reactivity Effects 0.000 description 3
238000011161 development Methods 0.000 description 3
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 3
238000009472 formulation Methods 0.000 description 3
230000004927 fusion Effects 0.000 description 3
230000028993 immune response Effects 0.000 description 3
125000001041 indolyl group Chemical group 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000002372 labelling Methods 0.000 description 3
ZAGRKAFMISFKIO-QMTHXVAHSA-N lysergic acid Chemical compound C1=CC(C2=C[C@H](CN([C@@H]2C2)C)C(O)=O)=C3C2=CNC3=C1 ZAGRKAFMISFKIO-QMTHXVAHSA-N 0.000 description 3
238000005259 measurement Methods 0.000 description 3
230000008569 process Effects 0.000 description 3
239000000700 radioactive tracer Substances 0.000 description 3
238000012216 screening Methods 0.000 description 3
229940076279 serotonin Drugs 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
ZRTJVRDXVSDKPX-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-acetylsulfanylpropanoate Chemical compound CC(=O)SCCC(=O)ON1C(=O)CCC1=O ZRTJVRDXVSDKPX-UHFFFAOYSA-N 0.000 description 2
238000005160 1H NMR spectroscopy Methods 0.000 description 2
WEVYAHXRMPXWCK-MICDWDOJSA-N 2-deuterioacetonitrile Chemical compound [2H]CC#N WEVYAHXRMPXWCK-MICDWDOJSA-N 0.000 description 2
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
206010003445 Ascites Diseases 0.000 description 2
XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
208000028017 Psychotic disease Diseases 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
150000001299 aldehydes Chemical class 0.000 description 2
230000000890 antigenic effect Effects 0.000 description 2
DCBDOYDVQJVXOH-UHFFFAOYSA-N azane;1h-indole Chemical group N.C1=CC=C2NC=CC2=C1 DCBDOYDVQJVXOH-UHFFFAOYSA-N 0.000 description 2
229940098773 bovine serum albumin Drugs 0.000 description 2
239000006227 byproduct Substances 0.000 description 2
125000004181 carboxyalkyl group Chemical group 0.000 description 2
239000000969 carrier Substances 0.000 description 2
ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
238000010668 complexation reaction Methods 0.000 description 2
238000006482 condensation reaction Methods 0.000 description 2
239000004020 conductor Substances 0.000 description 2
230000007423 decrease Effects 0.000 description 2
230000007547 defect Effects 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
229960003133 ergot alkaloid Drugs 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
125000004494 ethyl ester group Chemical group 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
238000005194 fractionation Methods 0.000 description 2
239000007789 gas Substances 0.000 description 2
238000004817 gas chromatography Methods 0.000 description 2
150000004676 glycans Chemical class 0.000 description 2
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
238000011835 investigation Methods 0.000 description 2
230000000155 isotopic effect Effects 0.000 description 2
239000003446 ligand Substances 0.000 description 2
238000011068 loading method Methods 0.000 description 2
UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 2
239000011654 magnesium acetate Substances 0.000 description 2
235000011285 magnesium acetate Nutrition 0.000 description 2
229940069446 magnesium acetate Drugs 0.000 description 2
239000000463 material Substances 0.000 description 2
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
229920001282 polysaccharide Polymers 0.000 description 2
239000005017 polysaccharide Substances 0.000 description 2
239000012254 powdered material Substances 0.000 description 2
239000002243 precursor Substances 0.000 description 2
238000000746 purification Methods 0.000 description 2
238000011084 recovery Methods 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 2
238000012546 transfer Methods 0.000 description 2
MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 2
CSKKDSFETGLMSB-NRZPKYKESA-N (-)-secologanin Chemical compound C=C[C@@H]1[C@H](CC=O)C(C(=O)OC)=CO[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CSKKDSFETGLMSB-NRZPKYKESA-N 0.000 description 1
QGKMIGUHVLGJBR-UHFFFAOYSA-M (4z)-1-(3-methylbutyl)-4-[[1-(3-methylbutyl)quinolin-1-ium-4-yl]methylidene]quinoline;iodide Chemical compound [I-].C12=CC=CC=C2N(CCC(C)C)C=CC1=CC1=CC=[N+](CCC(C)C)C2=CC=CC=C12 QGKMIGUHVLGJBR-UHFFFAOYSA-M 0.000 description 1
150000003923 2,5-pyrrolediones Chemical class 0.000 description 1
208000032484 Accidental exposure to product Diseases 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
241000700198 Cavia Species 0.000 description 1
241000221760 Claviceps Species 0.000 description 1
206010010904 Convulsion Diseases 0.000 description 1
IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
BVTJGGGYKAMDBN-UHFFFAOYSA-N Dioxetane Chemical compound C1COO1 BVTJGGGYKAMDBN-UHFFFAOYSA-N 0.000 description 1
101100284769 Drosophila melanogaster hemo gene Proteins 0.000 description 1
241000283086 Equidae Species 0.000 description 1
BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
108010044091 Globulins Proteins 0.000 description 1
102000006395 Globulins Human genes 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
208000004547 Hallucinations Diseases 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
241000254158 Lampyridae Species 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
238000006683 Mannich reaction Methods 0.000 description 1
206010027940 Mood altered Diseases 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
108010058846 Ovalbumin Proteins 0.000 description 1
241000237988 Patellidae Species 0.000 description 1
108700020962 Peroxidase Proteins 0.000 description 1
102000003992 Peroxidases Human genes 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
244000082988 Secale cereale Species 0.000 description 1
CSKKDSFETGLMSB-FUJZYWHJSA-N Secologanin Natural products C=C[C@@H]1[C@H](CC=O)C(C(=O)OC)=CO[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CSKKDSFETGLMSB-FUJZYWHJSA-N 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
239000004809 Teflon Substances 0.000 description 1
229920006362 Teflon® Polymers 0.000 description 1
241000473945 Theria <moth genus> Species 0.000 description 1
229920002807 Thiomer Polymers 0.000 description 1
102000002248 Thyroxine-Binding Globulin Human genes 0.000 description 1
108010000259 Thyroxine-Binding Globulin Proteins 0.000 description 1
208000003443 Unconsciousness Diseases 0.000 description 1
108010059993 Vancomycin Proteins 0.000 description 1
XUGUHTGSMPZQIW-UHFFFAOYSA-N [[4-(4-diazonioiminocyclohexa-2,5-dien-1-ylidene)cyclohexa-2,5-dien-1-ylidene]hydrazinylidene]azanide Chemical compound C1=CC(N=[N+]=[N-])=CC=C1C1=CC=C(N=[N+]=[N-])C=C1 XUGUHTGSMPZQIW-UHFFFAOYSA-N 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000004913 activation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
150000001371 alpha-amino acids Chemical class 0.000 description 1
235000008206 alpha-amino acids Nutrition 0.000 description 1
WYTGDNHDOZPMIW-RCBQFDQVSA-N alstonine Chemical compound C1=CC2=C3C=CC=CC3=NC2=C2N1C[C@H]1[C@H](C)OC=C(C(=O)OC)[C@H]1C2 WYTGDNHDOZPMIW-RCBQFDQVSA-N 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
238000007281 aminoalkylation reaction Methods 0.000 description 1
125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
238000007080 aromatic substitution reaction Methods 0.000 description 1
238000010170 biological method Methods 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
239000012472 biological sample Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000000133 brain stem Anatomy 0.000 description 1
244000309464 bull Species 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
150000007942 carboxylates Chemical class 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
208000015114 central nervous system disease Diseases 0.000 description 1
230000008859 change Effects 0.000 description 1
150000001793 charged compounds Chemical class 0.000 description 1
125000000068 chlorophenyl group Chemical group 0.000 description 1
238000004581 coalescence Methods 0.000 description 1
229960003920 cocaine Drugs 0.000 description 1
238000004040 coloring Methods 0.000 description 1
238000012875 competitive assay Methods 0.000 description 1
230000006957 competitive inhibition Effects 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000001212 derivatisation Methods 0.000 description 1
UZBQIPPOMKBLAS-UHFFFAOYSA-N diethylazanide Chemical compound CC[N-]CC UZBQIPPOMKBLAS-UHFFFAOYSA-N 0.000 description 1
LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
229960005156 digoxin Drugs 0.000 description 1
LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000002359 drug metabolite Substances 0.000 description 1
238000003255 drug test Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
238000001952 enzyme assay Methods 0.000 description 1
238000006345 epimerization reaction Methods 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
230000029142 excretion Effects 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
229960004279 formaldehyde Drugs 0.000 description 1
108010020862 formaldehyde-serum albumin Proteins 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
108010074605 gamma-Globulins Proteins 0.000 description 1
238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
230000036541 health Effects 0.000 description 1
229960001340 histamine Drugs 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
210000004408 hybridoma Anatomy 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
239000002117 illicit drug Substances 0.000 description 1
150000003949 imides Chemical class 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
229930005303 indole alkaloid Natural products 0.000 description 1
239000011261 inert gas Substances 0.000 description 1
150000002540 isothiocyanates Chemical class 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
239000011259 mixed solution Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
230000007510 mood change Effects 0.000 description 1
229960005181 morphine Drugs 0.000 description 1
238000005648 named reaction Methods 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
229940092253 ovalbumin Drugs 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
102000013415 peroxidase activity proteins Human genes 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
230000001337 psychedelic effect Effects 0.000 description 1
230000005855 radiation Effects 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
230000006798 recombination Effects 0.000 description 1
238000005215 recombination Methods 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
229920005989 resin Polymers 0.000 description 1
239000011347 resin Substances 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
230000021317 sensory perception Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
239000002904 solvent Substances 0.000 description 1
241000894007 species Species 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
229920003002 synthetic resin Polymers 0.000 description 1
239000000057 synthetic resin Substances 0.000 description 1
235000018553 tannin Nutrition 0.000 description 1
229920001864 tannin Polymers 0.000 description 1
239000001648 tannin Substances 0.000 description 1
BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical compound FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 description 1
RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
229940126585 therapeutic drug Drugs 0.000 description 1
150000003568 thioethers Chemical class 0.000 description 1
ATGUDZODTABURZ-UHFFFAOYSA-N thiolan-2-ylideneazanium;chloride Chemical compound Cl.N=C1CCCS1 ATGUDZODTABURZ-UHFFFAOYSA-N 0.000 description 1
238000006177 thiolation reaction Methods 0.000 description 1
229940034208 thyroxine Drugs 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
125000003944 tolyl group Chemical group 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
238000000825 ultraviolet detection Methods 0.000 description 1
MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
229960003165 vancomycin Drugs 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229940082632 vitamin b12 and folic acid Drugs 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
- C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
- C07D457/06—Lysergic acid amides
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/946—CNS-stimulants, e.g. cocaine, amphetamines

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Pharmacology & Pharmacy (AREA)
Physics & Mathematics (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Food Science & Technology (AREA)
Medicinal Chemistry (AREA)
Cell Biology (AREA)
Analytical Chemistry (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Peptides Or Proteins (AREA)
Media Introduction/Drainage Providing Device (AREA)

JP9519960A 1995-11-20 1996-11-20 Ｌｓｄのｎ−１−カルボキシアルキル誘導体 Ceased JPH11502419A (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US08/560,871 US5843682A (en)	1995-11-20	1995-11-20	N-1-carboxyalkyl derivatives of LSD
US08/560,871		1995-11-20
PCT/US1996/019266 WO1997019100A1 (en)	1995-11-20	1996-11-20	N-1-carboxyalkyl derivatives of lsd

Publications (1)

Publication Number	Publication Date
JPH11502419A true JPH11502419A (ja)	1999-03-02

Family

ID=24239712

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP9519960A Ceased JPH11502419A (ja)	1995-11-20	1996-11-20	Ｌｓｄのｎ−１−カルボキシアルキル誘導体

Country Status (6)

Country	Link
US (1)	US5843682A (2)
EP (1)	EP0830370B1 (2)
JP (1)	JPH11502419A (2)
CA (1)	CA2211385C (2)
DE (1)	DE69611758T2 (2)
WO (1)	WO1997019100A1 (2)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6207396B1 (en) *	1995-11-20	2001-03-27	Microgenics Corporation	Immunoassay reagents and methods for determination of LSD and LSD metabolites
US6063908A (en) *	1996-07-02	2000-05-16	Roche Diagnostics Corporation	Reagents for lysergic acid diethylamide immunoassay
WO1999042840A1 (en) *	1998-02-20	1999-08-26	Microgenics Corporation	Immunoassays for determination of lsd and lsd metabolites
US6306616B1 (en)	1998-03-27	2001-10-23	Microgenics Corporation	Adsorption type confirmatory assays
DE1066523T1 (de) *	1998-03-27	2001-09-20	Microgenics Corp., Pleasanton	Kontrollbestimmungsmethoden für drogen bestehend aus kleinen molekülen
US6548645B1 (en)	1999-06-18	2003-04-15	Microgenetics Corporation	Immunoassay for 2-oxo-3-hydroxy LSD
US6794496B2 (en) *	2000-04-07	2004-09-21	Roche Diagnostics Corporation	Immunoassay for LSD and 2-oxo-3-hydroxy-LSD
NZ511705A (en) *	2001-05-14	2004-03-26	Horticulture & Food Res Inst	Methods and rapid immunoassay device for detecting progesterone and other steroids
US20060223998A1 (en) *	2005-03-30	2006-10-05	Fang-Jie Zhang	Synthetic LSD metabolite for preparing haptens used in an LSD metabolite immunoassay
WO2018064465A1 (en)	2016-09-29	2018-04-05	The Regents Of The University Of California	Compounds for increasing neural plasticity
JP7770673B2 (ja)	2019-02-27	2025-11-17	ザリージェンツオブザユニバーシティオブカリフォルニア	脳障害を治療するためのアゼピノ－インドール及び他の複素環化合物
CA3214953A1 (en) *	2021-04-13	2022-10-20	The Regents Of The University Of California	Tetracyclic compounds for treating brain disorders
AU2022416279A1 (en)	2021-12-15	2024-07-25	Delix Therapeutics, Inc.	Phenoxy and benzyloxy substituted psychoplastogens and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3249617A (en) *		1966-05-03		Alkylated d-lyserglc acid
CH344731A (de) *	1956-05-18	1960-02-29	Sandoz Ag	Verfahren zur Herstellung von neuen, am Indolstickstoff alkylierten Derivaten der Lysergsäure-Reihe
CH396024A (de) *	1960-08-22	1965-07-31	Sandoz Ag	Verfahren zur Herstellung von neuen Hydrierungsprodukten der Lysergsäure-Reihe
US4375414A (en) *	1971-05-20	1983-03-01	Meir Strahilevitz	Immunological methods for removing species from the blood circulatory system and devices therefor
US4236893A (en) *	1979-04-09	1980-12-02	Minnesota Mining And Manufacturing Company	Method for the assay of classes of antigen-specific antibodies
US4708929A (en) *	1984-10-29	1987-11-24	Microgenics Corporation	Methods for protein binding enzyme complementation assays
DE3919915A1 (de) *	1989-06-19	1990-12-20	Boehringer Mannheim Gmbh	Aminoalkylmaleimide und davon abgeleitete hapten- und antigenderivate sowie konjugate mit peptiden oder proteinen
IT1232350B (it) *	1989-08-04	1992-01-28	Poli Ind Chimica Spa	Nuovi ergolinici derivati dalla prolina e strutture correlate con attivita' dopaminergica.
EP0683793A4 (en) *	1993-01-21	1997-04-09	Univ Georgia Res Found	VACCINE AND METHODS FOR PREVENTION AND TREATMENT OF Fescue Toxicity In Herbivorous Animals.
FR2725023B1 (fr) *	1994-09-28	1997-01-31	Gks Technologies	Diagnostic direct d'haptenes

1995
- 1995-11-20 US US08/560,871 patent/US5843682A/en not_active Expired - Fee Related
1996
- 1996-11-20 CA CA002211385A patent/CA2211385C/en not_active Expired - Fee Related
- 1996-11-20 DE DE69611758T patent/DE69611758T2/de not_active Expired - Fee Related
- 1996-11-20 EP EP96942873A patent/EP0830370B1/en not_active Expired - Lifetime
- 1996-11-20 JP JP9519960A patent/JPH11502419A/ja not_active Ceased
- 1996-11-20 WO PCT/US1996/019266 patent/WO1997019100A1/en not_active Ceased

Also Published As

Publication number	Publication date
DE69611758T2 (de)	2001-05-23
CA2211385C (en)	2001-03-20
WO1997019100A1 (en)	1997-05-29
DE69611758D1 (de)	2001-03-15
EP0830370B1 (en)	2001-02-07
CA2211385A1 (en)	1997-05-29
EP0830370A4 (2)	1998-03-25
EP0830370A1 (en)	1998-03-25
US5843682A (en)	1998-12-01

Legal Events

Date

Code

Title

Description

2004-10-05

A131

Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20041005

2005-03-17

A313

Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20050228

2005-04-05

A02

Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20050405

Publication	Publication Date	Title
CN104755479A (zh)	2015-07-01	利培酮和帕潘立酮的半抗原
EP0830370B1 (en)	2001-02-07	N-1-carboxyalkyl derivatives of lsd
EP0816364B1 (en)	2004-01-02	Reagents for lysergic acid diethylamide immunoassay
JPH05249112A (ja)	1993-09-28	酵素阻害剤を使用する均質系免疫検定法
HOSODA et al.	1986	Bridging phenomena in steroid immunoassays. The effect of bridge length on sensitivity in enzyme immunoassay
JPS59163566A (ja)	1984-09-14	新規酵素結合免疫分析法
EP2998743B1 (en)	2018-02-21	Detection of indazole synthetic cannabinoids
US6207396B1 (en)	2001-03-27	Immunoassay reagents and methods for determination of LSD and LSD metabolites
US6946547B2 (en)	2005-09-20	Ecstasy-class analogs and use of same in detection of ecstasy-class compounds
US6306616B1 (en)	2001-10-23	Adsorption type confirmatory assays
US6140137A (en)	2000-10-31	Conjugates and specific immunoassays for the methadone metabolite 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine
US9777069B2 (en)	2017-10-03	Compositions and methods for detection of methadone metabolite
US6262265B1 (en)	2001-07-17	Non-hydrolyzable analogs of heroin metabolites suitable for use in immunoassay
WO1998026644A2 (en)	1998-06-25	Confirmatory assays for small molecule drugs
US20020192703A1 (en)	2002-12-19	Immunoassay reagents and methods for determination of LSD and LSD metabolites
Skerritt et al.	2000	Development of immunoassays for tyramine and tryptamine toxins of Phalaris aquatica L.
US6548645B1 (en)	2003-04-15	Immunoassay for 2-oxo-3-hydroxy LSD
Ishikawa et al.	1988	Methods for enzyme-labeling of antigens antibodies and their fragments
US10591497B2 (en)	2020-03-17	Immunoassay for synthetic cannabinoids of the adamantyl indazole/indole-3-carboxamide family
EP3185015A1 (en)	2017-06-28	Opioid detection
JP2605418B2 (ja)	1997-04-30	ハプテンである抗原に対し高親和性を持つ抗体
Kerrigan et al.	1998	Optimization and immunological characterization of a photochemically coupled lysergic acid diethylamide (LSD) immunogen
Albassam	1979	The development of enzyme immunoassays for hormones and drugs
Tanaka	2012	Eiji Ishikawa, Seiichi Hashida, Takeyuki Kohno and